Company Profile
Mustang Bio Stock Price, News & Analysis
- Ticker:
- MBIO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.58 USD (-3.64%)
Close
Last updated: August 6, 2026
5.77M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, MBIO closed down 3.64% at $0.5752. No new same-company headline was identified in the current news window.
Company overview
Business overview
Mustang Bio is a cell and gene therapy company focused on oncology, including CAR-T and other engineered cell approaches. Its story is built around the possibility that targeted cell therapies can create differentiated outcomes in hard-to-treat cancers.
Geographic Base and Sector Classification
Mustang Bio is headquartered in the United States and listed on NASDAQ, placing it in the small-cap oncology biotech universe. It sits squarely in development-stage cell therapy rather than commercial large-cap pharma.
Business Model Characteristics
The company depends on clinical data, manufacturing execution, and access to capital to keep programs moving. Investors usually focus on trial updates, safety and efficacy signals, and whether the platform can survive long enough to reach meaningful commercialization.
Position Within the Biotechnology Landscape
Mustang Bio occupies a high-volatility cell therapy niche within biotech. Because it is still heavily development-driven, the stock tends to respond sharply to readouts, financing, and strategic partnerships.
Future catalysts
Mustang Bio’s catalysts are its cell-therapy pipeline, especially any update that clarifies whether the CAR-T and gene-therapy assets still have enough momentum. The stock remains highly data-sensitive.
Recent news
- 01
- 02
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement
Source: Mustang Bio
- 03
Mustang Bio Announces Sale of Fixed Assets and Exit of Facility
Source: Mustang Bio
- 04
Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
Source: Mustang Bio
- 05
Mustang Bio Announces Closing of $8 Million Public Offering
Source: Mustang Bio
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Mustang Bio (MBIO)?
Mustang Bio (MBIO) most recently closed at 0.58 USD, a -3.64% move versus the previous session.
What is the market cap of Mustang Bio (MBIO)?
Mustang Bio currently has a market capitalization of 5.77M USD on BioPharmSignal.
What does Mustang Bio do?
Mustang Bio is a cell and gene therapy company focused on oncology, including CAR-T and other engineered cell approaches. Its story is built around the possibility that targeted cell therapies can create differentiated outcomes in hard-to-treat cancers.
On which exchange is MBIO stock listed?
Mustang Bio (MBIO) is associated with NASDAQ, United States, Biopharma.
What is CAR-T?
Mustang Bio’s catalysts are its cell-therapy pipeline, especially any update that clarifies whether the CAR-T and gene-therapy assets still have enough momentum.
Which conditions is Mustang Bio targeting with CAR-T?
Mustang Bio is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Mustang Bio describe recent progress with CAR-T?
Mustang Bio’s catalysts are its cell-therapy pipeline, especially any update that clarifies whether the CAR-T and gene-therapy assets still have enough momentum.
What is Mustang?
Mustang Bio is a cell and gene therapy company focused on oncology, including CAR-T and other engineered cell approaches.